WNT5A and posterior cortical atrophy: The WNT ligand WNT-5A was targeted using a WNT-5A-mimicking peptide named Foxy-5.456 Foxy-5 was evaluated in a phase 1 clinical trial in patients with solid malignant tumors including PCa (Table 10).